Nat Med: Efficacy analysis of mRNA-1273 vaccine against SARS-CoV-2 Omicron and Delta variants

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron 38 (B.
1.
1.
529) variant that emerged in December 2021 contains multiple novel spike (S) protein mutations, SARS-CoV-2 -The CoV-2 Omicron (B.
1.
1.
529) variant is highly transmissible and has potential for immune escape
.

Recently, a research article was published in the top medical journal Nature Medicine.
In this study, the researchers conducted a negative case-control study to evaluate the mRNA-1273 vaccine against infection with the Omicron strain or the Delta strain.
and effectiveness of hospitalization
.

This large, diverse study population included 26,683 SARS-CoV-2-positive cases whose variants were identified by S gene target failure status (16% Delta, 84% Omicron)
.

The efficacy of 3 doses of vaccine was 93.
7% (92.
2-94.
9%) and 86.
0% (78.
1-91.
1%) for Delta strain infection at 14-60 days and 60 days, respectively, and 14-60% for Omicron infection.
71.
6% (69.
7-73.
4%) and 47.
4% (40.
5-53.
5%) for 60 days and more than 60 days, respectively
.

Thus, the results of this study show that the 3-dose mRNA-1273 vaccine has high and durable efficacy against Delta infection, but less efficacy against Omicron infection, especially in immunocompromised patients.
in the crowd
.

Hung Fu Tseng, et al.